Skip to main content

Advertisement

SpringerLink
Log in

Hepatitis B Virus Infection in US Correctional Facilities: A Review of Diagnosis, Management, and Public Health Implications

  • Published:
Journal of Urban Health Aims and scope Submit manuscript

Abstract

Among the blood-borne chronic viral infections, hepatitis B virus (HBV) infection is one that is not only treatable but also preventable by provision of vaccination. Despite the availability of HBV vaccine for the last 15 years, more than 1.25 million individuals in the USA have chronic HBV infection, and about 5,000 die each year from HBV-related complications. From a societal perspective, access to treatment of chronic viral infections, like HIV and viral hepatitis, is highly cost-effective and has lasting benefits by reducing risk behaviors, morbidity, mortality, as well as disease transmission in the community. Individuals in correctional facilities are specially predisposed to such chronic viral infections because of their high-risk behaviors. The explosion of incarceration in the USA over the last few decades and the disproportionate burden of morbidity and mortality from chronic infections among the incarcerated have put incredible strains on an overcrowded system that was not originally designed to provide comprehensive medical care for chronic illnesses. Recently, there has been a call to address medical care for individuals with chronic medical conditions in correctional settings, including those with infectious diseases. The economic and public health burden of chronic hepatitis B and its sequelae, including cirrhosis and hepatocellular carcinoma, is felt most prominently in managed care settings with limited budgets, like correctional facilities. Prevalence of HBV infection among the incarcerated in the USA is fivefold that of the general population. We present a review of diagnosis, prevention, and the recently streamlined treatment guidelines for management of HBV infection in correctional settings, and discuss the implications and public health impact of these measures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bureau of Justice Statistics, US Department of Justice. Bureau of Justice Statistics, 2006. Available at: http://www.ojp.usdoj.gov/bjs/prisons.htm. Accessed Dec 21, 2007.

  2. Harrison PM, Beck AJ. Prisoners in 2005. Washington DC: US Department of Justice, Bureau of Justice Statistics; 2006.

    Google Scholar 

  3. Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health. 2002;92:1789–1794.

    Article  PubMed  Google Scholar 

  4. Altice FL, Marinovich MA, Khoshnood K, Blankenship K, Springer S, Selwyn P. Correlates of HIV Infection Among Incarcerated Women. J Urban Health. 2005. 82(2):312–326 doi:10.1093/jurban/jti055.

    PubMed  Google Scholar 

  5. Health Status of Soon-to-be-Released Inmates. A Report to Congress, vol. 2. Washington, DC: National Commission on Correctional Health Care; 2002.

  6. Conklin TJ, Lincoln T, Flanigan TP. A public health model to connect correctional health care with communities. Am J Public Health. 1998;88(8):1249–1250.

    PubMed  CAS  Google Scholar 

  7. Altice FL, Springer SA. In: Mayer K, Pfizer HF, eds. Management of HIV/AIDS in Correctional Settings The AIDS Pandemic: Impact on Science and Society. San Diego, CA: Elsevier; 2005.

    Google Scholar 

  8. World Health Organization (WHO). Wkly Epidemiol Rec 79(28):253–264; 2004.

    Google Scholar 

  9. McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health. 1999;89:14–18.

    PubMed  CAS  Google Scholar 

  10. CDC. US disease burden data 1980–2006. Available at: http://www.cdc.gov/ncidod/diseases/hepatitis/resource/index.htm#surveillance. Accessed on Oct 30, 2007.

  11. Khan A, Goldstein S, Williams I, Bell B, Mast E. Opportunities for hepatitis B prevention in correctional facilities and sexually transmitted disease treatment settings. Antivir Ther. 2000;5(suppl 1):22.

    Google Scholar 

  12. Goldstein ST, Alter MJ, Williams IT, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982–1998: implications for vaccination programs. J Infect Dis. 2002. 185:713–719 doi:10.1086/339192.

    Article  PubMed  Google Scholar 

  13. Hull HF, Lyons LH, Mann JM, Hadler SC, Steece R, Skeels MR. Incidence of hepatitis B in the penitentiary of New Mexico. Am J Public Health. 1985;75:1213–1214.

    Article  PubMed  CAS  Google Scholar 

  14. Centers for Disease Control and Prevention. Transmission of hepatitis B virus in correctional facilities–Georgia, January 1999-June 2002. MMWR Morb Mortal Wkly Rep. 2004;53(30):678–681.

    Google Scholar 

  15. Centers for Disease Control and Prevention. Hepatitis B outbreak in a state correctional facility, 2000. MMWR Morb Mortal Wkly Rep. 2001;50(25):529–532.

    Google Scholar 

  16. Khan A, Simard E, Wurtzel H, et al. The prevalence, risk factors, and incidence of hepatitis B virus infection among inmates in a state correctional facility [Abstract]. In: Program and abstracts of the 130th Annual Meeting of the American Public Health Association, Philadelphia, Pennsylvania, 2002.

  17. Ruiz JD, Mikanda J. Seroprevalence of HIV, hepatitis B, hepatitis C, and risk behaviors among inmates entering the California Correctional System. California Department of Health Services, Office of AIDS, HIV/AIDS Epidemiology Office, March 1996.

  18. Mikl J, Dzierbicki A, Smith PF, Greifinger R, Wright L, Morse DL. Trends in HIV infection rates among New York State (NYS) Prison Inmates, 1987–97. Poster abstract no. 23516 presented at 12th World AIDS Congress, June 30, 1998, Geneva, Switzerland.

  19. Weinbaum C, Lyerla R, Margolis HS. Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2003;52(RR-1):1–36.

    PubMed  Google Scholar 

  20. Macalino GE, Salas CM, Towe CW, et al. Incidence and community prevalence of HIV and other blood borne pathogens among incarcerated women in Rhode Island [Abstract]. Presented at the National HIV Prevention Conference. Atlanta, GA: US Department of Health and Human Services, CDC; 1999.

  21. Charuvastra A, Stein J, Schwartzapfel B, et al. Hepatitis B vaccination practices in state and federal prisons. Public Health Rep. 2001;116:203–209.

    PubMed  CAS  Google Scholar 

  22. McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985;151:599–603.

    PubMed  CAS  Google Scholar 

  23. Iloeje UH, Yang HI, Su J. HBV viral load less than 104 copies/mL is associated with significant risk of hepatocellular carcinoma in chronic hepatitis B (CHB) patients: an update from the R.E.V.E.A.L.-HBV Study. In: Program and abstracts of the 58th Annual Meeting of the American Association for the Study of Liver Diseases; November 2–6, 2007; Boston, MA. Abstract 907.

  24. Chu CJ, Keeffe EB, Han SH, et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology. 2003. 125(2):444–451 doi:10.1016/S0016-5085(03)00895-3.

    Article  PubMed  Google Scholar 

  25. Chan HL, Hui AY, Wong ML, Tse AML, Hung LCT, Sung JJY. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut. 2004. 53:1494–1498 doi:10.1136/gut.2003.033324.

    Article  PubMed  Google Scholar 

  26. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology. 2002. 122:1756–1762 doi:10.1053/gast.2002.33588.

    Article  PubMed  CAS  Google Scholar 

  27. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005. 365:123–129 doi:10.1016/S0140-6736(05)17701-0.

    Article  PubMed  CAS  Google Scholar 

  28. Di Marco V, Lo Iacono O, Camma C, et al. The long-term course of chronic hepatitis B. Hepatology. 1999. 30:257–264 doi:10.1002/hep.510300109.

    Article  PubMed  Google Scholar 

  29. Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology. 1995;21:77–82.

    PubMed  CAS  Google Scholar 

  30. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002. 347:168–174 doi:10.1056/NEJMoa013215.

    Article  PubMed  CAS  Google Scholar 

  31. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006. 295(1):65–73 doi:10.1001/jama.295.1.65.

    Article  PubMed  CAS  Google Scholar 

  32. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006. 130:678–686 doi:10.1053/j.gastro.2005.11.016.

    Article  PubMed  Google Scholar 

  33. Ahn SH, Han KH, Park JY, et al. Association between hepatitis B virus infection and HLA-DR type in Korea. Hepatology. 2000. 31(6):1371–1373 doi:10.1053/jhep.2000.7988.

    Article  PubMed  CAS  Google Scholar 

  34. Chu RH, Ma LX, Wang G, Shao LH. Influence of HLA-DRB1 alleles and HBV genotypes on interferon-alpha therapy for chronic hepatitis B. World J Gastroenterol. 2005;11(30):4753–4757.

    PubMed  CAS  Google Scholar 

  35. Centers for Disease Control and Prevention. Notice to readers update recommendations to prevent hepatitis B virus transmission—United States. MMWR Morb Mortal Wkly Rep. 1999;48(2):33–34.

    Google Scholar 

  36. Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1991;40(RR-13):1–25.

    Google Scholar 

  37. Charuvastra A, Stein J, Schwartzapfel B, et al. Hepatitis B vaccination practices in state and federal prisons. Public Health Rep. 2001;116:203–209.

    PubMed  CAS  Google Scholar 

  38. Bick JA. Infection control in jails and prisons. Clin Infect Dis. 2007. 45:1047–1055 doi:10.1086/521910.

    Article  PubMed  Google Scholar 

  39. Bond WW, Favero MS, Petersen NJ, Gravelle CR, Ebert JW, Maynard JE. Survival of hepatitis B virus after drying and storage for one week. Lancet. 1981. 1(8219):550–551 doi:10.1016/S0140-6736(81)92877-4.

    Article  PubMed  CAS  Google Scholar 

  40. Petersen NJ, Barrett DH, Bond WW, et al. Hepatitis B surface antigen in saliva, impetiginous lesions, and the environment in two remote Alaskan villages. Appl Environ Microbiol. 1976;32(4):572–574.

    PubMed  CAS  Google Scholar 

  41. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States—recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR. 2006;55(RR-16):1–33.

    PubMed  Google Scholar 

  42. Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine. 2005. 23:2902–2908 doi:10.1016/j.vaccine.2004.11.057.

    Article  PubMed  CAS  Google Scholar 

  43. Wright NM, Campbell TL, Tompkins CN. Comparison of conventional and accelerated hepatitis B immunisation schedules for homeless drug users. Commun Dis Public Health. 2002;5:324–326.

    PubMed  CAS  Google Scholar 

  44. Altice FL, Bruce RD, Walton MR, Buitrago MI. Adherence to hepatitis B virus vaccination at syringe exchange sites. J Urban Health. 2005. 82(1):151–161 doi:10.1093/jurban/jti016.

    PubMed  Google Scholar 

  45. Lok AS, McMahon J. AASLD practice guidelines for chronic hepatitis B. Hepatology. 2007. 45(2):507–539 doi:10.1002/hep.21513.

    Article  PubMed  CAS  Google Scholar 

  46. Keeffe EB, Dieterich DT, Han SB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol. 2006. 4:936–962 doi:10.1016/j.cgh.2006.05.016.

    Article  PubMed  CAS  Google Scholar 

  47. Gish RG. Improving outcomes for patients with chronic hepatitis B. Curr Gastroenterol Rep. 2007. 9(1):14–22 doi:10.1007/s11894-008-0016-9.

    Article  PubMed  Google Scholar 

  48. Chang TT, Gish GR, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis. N Engl J Med. 2006. 354:1001–1010 doi:10.1056/NEJMoa051285.

    Article  PubMed  CAS  Google Scholar 

  49. Marcellin P, Buti M, Krastev Z, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): study GS-US-174-0102. In: Program and abstracts of the 58th Annual Meeting of the American Association for the Study of Liver Diseases; November 2–6, 2007; Boston, Massachusetts. Abstract LB2.

  50. Buti M, Hadziyannis S, Mathurin P. Tenofovir Disoproxil Fumarate (TDF) is Highly Active for Treatment of Chronic Hepatitis B (CHB) in Patients With Cirrhosis. Abstract presented at 43rd Annual Meeting of the European Association for the Study of the Liver; April 23–27, 2008; Milan, Italy

  51. Heathcote E, Gane E, DeMan R, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): study GS-US-174-0103. Program and abstracts of the 58th Annual Meeting of the American Association for the Study of Liver Diseases; November 2–6, 2007; Boston, MA. Abstract LB6.

  52. Gish R, Chang TT, Lai CL, et al. Hepatitis B surface antigen loss in antiviral-treated patients with HBeAg-positive chronic hepatitis B infection: observations from antiviral-naive patients treated with entecavir or lamivudine. Hepatology. 2006;44:558A.

    Google Scholar 

  53. Korevaar A, Moucari R, Asselah T, et al. High rates of HBsAg seroconversion in chronic hepatitis B patients responding to interferon therapy: a long-term follow-up study. In: Program and abstracts of the 58th Annual Meeting of the American Association for the Study of Liver Diseases; November 2–6, 2007; Boston.

  54. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol. 2007. 5:890–897 doi:10.1016/j.cgh.2007.05.004.

    Article  PubMed  Google Scholar 

  55. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003. 125:1714–1722 doi:10.1053/j.gastro.2003.09.033.

    Article  PubMed  CAS  Google Scholar 

  56. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999. 30:1302–1306 doi:10.1002/hep.510300525.

    Article  PubMed  CAS  Google Scholar 

  57. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil (ADV) in HBeAg+ chronic hepatitis B patients: increasing serologic, virologic, and biochemical response over time. Hepatology. 2004. 40(Suppl 1):665A doi:10.1002/hep.20257.

    Google Scholar 

  58. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005. 352:2673–2681 doi:10.1056/NEJMoa042957.

    Article  PubMed  CAS  Google Scholar 

  59. Lai CL, Gane E, Hsu CW, et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. Hepatology. 2006;44(4):222A.

    Google Scholar 

  60. van Bommel F, Mauss S, Schurmann D, et al. No evidence for tenofovir resistance in patients with lamivudine-resistant HBV infection during long-term treatment for up to 5 years. Hepatology. 2006. 44(Suppl):A549 (abstract)doi:10.1002/hep.21253.

    Google Scholar 

  61. Lee HS, Chung YH, Lee KS, et al. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology. 2006. 43:982–988 doi:10.1002/hep.21166.

    Article  PubMed  CAS  Google Scholar 

  62. Han S, Chang TT, Chao YC, et al. Four-year entecavir treatment in nucleoside-naive HbeAg+ patients: results from studies ETV-022 and -901. Hepatology. 2007;46:654A.

    Google Scholar 

  63. Manns M, Jeffers L, Dalekos G. The antiviral response to tenofovir is comparable in lamivudine (LAM)-naïve and LAM-experienced subjects treated for chronic hepatitis B (CHB). Abstract presented at 43rd Annual Meeting of the European Association for the Study of the Liver; April 23-27, 2008; Milan, Italy

  64. van Bömmel F, De Man RA, Petersen J. A Multicenter analysis of antiviral response to tenofovir in HBV mono-infected patients with prior nucleos(t)ide analogue experience. Abstract presented at 43rd Annual Meeting of the European Association for the Study of the Liver; April 23–27, 2008; Milan, Italy.

  65. Berg T, Moller B, Trinh H. Tenofovir (TDF) Versus emtricitabine plus TDF for treatment of chronic hepatitis B in subjects with persistent viral replication receiving adefovir dipivoxil (ADV). Abstract presented at 43rd Annual Meeting of the European Association for the Study of the Liver; April 23–27, 2008; Milan, Italy

  66. Hui CK, Zhang HY, Bowden S, et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine versus adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol. 2008. 48(5):714–720 doi:10.1016/j.jhep.2007.10.013.

    Article  PubMed  CAS  Google Scholar 

  67. Sung JJY, Lai JY, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol. 2008. 48(5):725–735 doi:10.1016/j.jhep.2007.12.026.

    Article  CAS  Google Scholar 

  68. Xu WM, Cui YT, Wang L, et al. Efficacy and safety of lamivudine in late pregnancy for the prevention of mother-child transmission of hepatitis B: a multicenter, randomised, double-blind, placebo-controlled study (abstr). Hepatology. 2004;40:272A–273A.

    Google Scholar 

  69. Lee JS, Mullaney S, Bronson R, et al. Transplacental antiretroviral therapy with 9-(2-phosphonylmethoxyethyl)adenine is embryotoxic in transgenic mice. J Acquir Immune Defic Syndr. 1991. 4(9):833–838 doi:10.1097/00126334-199109000-00001.

    PubMed  CAS  Google Scholar 

  70. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet. 2002. 360:1921–1926 doi:10.1016/S0140-6736(02)11913-1.

    Article  PubMed  Google Scholar 

  71. Bodsworth N, Donovan B, Nightingale BN. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis. 1989;160(4):577–582.

    PubMed  CAS  Google Scholar 

  72. Guidelines for Use of Antiretroviral Agents in HIV-1 infected adults and adolescents. Available at: http://aidsinfo.nih.gov/Guidelines. Accessed on Jan. 2008.

  73. McMahon M, Jilek B, Brennan T, et al. The anti-hepatitis B drug entecavir inhibits HIV-1 replication and selects HIV-1 variants resistant to antiretroviral drugs. Abstract presented at the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 2007.

  74. Lin L, Verslype C, van Pelt JF, van Ranst M, Fevery J. Viral interaction and clinical implications of coinfection of hepatitis C virus with other hepatitis viruses. Eur J Gastroenterol Hepatol. 2006. 18(12):1311–1319 (review)doi:10.1097/01.meg.0000243881.09820.09.

    Article  PubMed  Google Scholar 

  75. Saitta C, Pontisso P, Brunetto MR, et al. Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy. Antivir Ther. 2006;11(7):931–934.

    PubMed  CAS  Google Scholar 

  76. Bruix J, Sherman M. AASLD practice guidelines: management of hepatocellular carcinoma. Hepatology. 2005. 42(5):1208–1236 doi:10.1002/hep.20933.

    Article  PubMed  Google Scholar 

  77. Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis. 2004. 38(12):1754–1760 doi:10.1086/421392.

    Article  PubMed  CAS  Google Scholar 

  78. Kwiatkowski CF, Fortuin Corsi K, Booth RE. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction. 2002. 97(10):1289–1294 doi:10.1046/j.1360-0443.2002.00208.x.

    Article  PubMed  Google Scholar 

  79. Pisu M, Meltzer MI, Lyerla R. Centers for Disease Control and Prevention (CDC). Cost-effectiveness of hepatitis B vaccination of prison inmates. Vaccine. 2002. 21(3–4):312–321 doi:10.1016/S0264-410X(02)00457-7.

    Article  PubMed  Google Scholar 

  80. Enriquez AD, Campbell MS, Reddy KR. Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis. Aliment Pharmacol Ther. 2007;26:383–391.

    Article  PubMed  CAS  Google Scholar 

  81. Lee TA, Veenstra DL, Iloeje UH, Sullivan SD. Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol. 2004. 38:S144–S147 doi:10.1097/00004836-200411003-00005.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to acknowledge funding from the Bristol-Myers Squibb Virology Research Fellowship (SG) and the National Institute on Drug Abuse (FLA) (K24-DA017072).

Author information

Authors and Affiliations

  1. Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, 135 College Street, Suite 323, New Haven, CT, 06510-2283, USA

    Shaili Gupta & Frederick L. Altice

Authors
  1. Shaili Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frederick L. Altice
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shaili Gupta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gupta, S., Altice, F.L. Hepatitis B Virus Infection in US Correctional Facilities: A Review of Diagnosis, Management, and Public Health Implications. J Urban Health 86, 263–279 (2009). https://doi.org/10.1007/s11524-008-9338-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11524-008-9338-z

Keywords

Search

Navigation